INCREASED SYNTHESIS OF PROSTACYCLIN AND THROMBOXANE IN HUMAN OVARIAN MALIGNANCY

Authors:
  • LVLU VIINIKKA
    LU VIINIKKA
  • RYRO YLIKORKALA
    RO YLIKORKALA

  • 1 May 1988
    • journal article
    • research article
    • Vol. 48  (9) , 2396-2398
    • PMID:3281748
Abstract
To study the production of antiaggregatory prostacyclin (PGI2) and proaggregatory thromboxane (TxA2) by ovarian tumors, we incubated pieces of benign and malignant ovarian tissue in vitro, and measured by radioimmunoassay the release of 6-ketoprostaglandin F1a (6-keto-PGF1a) (a hydration product of PGI2) and thromboxane B2 (TxB2) (a hydration production of TxA2) Healthy ovary (n = 10) produced both 6-keto-PGF1.alpha. [mean, 8.9; 95% confidence interval (CI) from 5.4 to 15.2 ng/mg protein/ min] and TXB2 (mean, 1.9 ng/ml protein/min, 95% calcium from 1.0 to 3.7 ng/mg protein/min). The production of 6-keto-PGF1a (mean, 12.2; 95% CI from 7.7 to 19.3 ng/mg protein/min and that of TxB2 (mean, 4.8 95% CI from 2.1 to 11.9 ng/mg protein/min) by benign cystic tumors (n = 12) was normal. Ovarian anaplastic cancer and adenocarcinoma (n = 12) produced 6-keto-PGF1a on average 11.6-fold (95% CI from 5.2 to 26.0) 6-keto-PGF1a and TxB2 an average 30.0-fold (95% CI from 13.5 to 66.7) over production by healthy ovaries, and the ratio of 6-keto-PGF1.alpha. to breast cancer, tubal cancer, and colon cancer produced increasingly 6-keto-PGF1a (mean, 20.7 ng/mg protein/min) and TxB2 (5.1 ng/mg protein/ min). The dominance of TxA2 in human ovarian cancer may contribute to the aggressing growth and spreading of this tumor.